Knopp reports positive preclinical data for neonatal epilepsy drug candidate

Knopp reports positive preclinical data for neonatal epilepsy drug candidate

Source: 
Pharmaceutical Business Review
snippet: 

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida.